Altimmune Could Find A Partner For Its Phase 3 Exercise

Back in October, I rated Altimmune (NASDAQ: ALT ) a hold, based on the fact that while I liked the prospects of ALT's incretin drug, pemvidutide, I wanted to hear the outcome of the company's end-of-phase 2 (EOP2) meeting with the U.S. FDA. ThisScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disc ...